Suppression of neuroinflammation and α-synuclein oligomerization by rotarod walking exercise in subacute MPTP model of Parkinson's disease

[1]  Hee-Sun Kim,et al.  Neurogenic effects of rotarod walking exercise in subventricular zone, subgranular zone, and substantia nigra in MPTP-induced Parkinson’s disease mice , 2022, Scientific Reports.

[2]  Hee-Sun Kim,et al.  Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson’s Disease Mouse Models , 2022, International journal of molecular sciences.

[3]  Y. Vandermeeren,et al.  Bimanual motor skill learning with robotics in chronic stroke: comparison between minimally impaired and moderately impaired patients, and healthy individuals , 2021, Journal of NeuroEngineering and Rehabilitation.

[4]  P. Tucci,et al.  A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases , 2022, Frontiers in Cellular Neuroscience.

[5]  Wugang Hou,et al.  Sevoflurane preconditioning protects experimental ischemic stroke by enhancing anti‐inflammatory microglia/macrophages phenotype polarization through GSK‐3β/Nrf2 pathway , 2021, CNS neuroscience & therapeutics.

[6]  Shin-Da Lee,et al.  Effects of Treadmill Exercise on Neural Mitochondrial Functions in Parkinson’s Disease: A Systematic Review of Animal Studies , 2021, Biomedicines.

[7]  P. Chiang,et al.  Low-Intensity Pulsed Ultrasound Enhances Neurotrophic Factors and Alleviates Neuroinflammation in a Rat Model of Parkinson's Disease. , 2021, Cerebral cortex.

[8]  E. Chang,et al.  Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease , 2021, Brain and behavior.

[9]  Tingting Zheng,et al.  Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease , 2021, Neurochemistry International.

[10]  Hee-Sun Kim,et al.  Papaverine inhibits α-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson's disease. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  Yun Yu,et al.  Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/ HIF-1α pathway. , 2020, International immunopharmacology.

[12]  X. Ye,et al.  Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-κB Pathway in Parkinson’s Disease , 2020, Frontiers in Pharmacology.

[13]  Hee-Sun Kim,et al.  The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson’s disease mouse models , 2019, Journal of Neuroinflammation.

[14]  M. McKeown,et al.  Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[15]  Jia-Da Li,et al.  The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases , 2019, Front. Neurosci..

[16]  Man Li,et al.  AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression , 2019, Journal of Neuroinflammation.

[17]  Eyal Oren,et al.  Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, The Lancet. Neurology.

[18]  J. Winkler,et al.  Perturbation Treadmill Training Improves Clinical Characteristics of Gait and Balance in Parkinson's Disease. , 2019, Journal of Parkinson's disease.

[19]  Xiaomei Wang,et al.  Knockdown of cathepsin D protects dopaminergic neurons against neuroinflammation‐mediated neurotoxicity through inhibition of NF‐κB signalling pathway in Parkinson's disease model , 2019, Clinical and experimental pharmacology & physiology.

[20]  Z. Andrews,et al.  Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson’s Disease , 2018, Journal of Parkinson's disease.

[21]  Meryem A Yücel,et al.  Assessing bimanual motor skills with optical neuroimaging , 2017, Science Advances.

[22]  Xia Shen,et al.  Long-term effects of exercise and physical therapy in people with Parkinson disease , 2017, Nature Reviews Neurology.

[23]  E. Ma,et al.  AMPK Maintains Cellular Metabolic Homeostasis through Regulation of Mitochondrial Reactive Oxygen Species. , 2017, Cell reports.

[24]  M. Hallett,et al.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[25]  C. Knight,et al.  Effects of a low-resistance, interval bicycling intervention in Parkinson’s Disease , 2017, Physiotherapy theory and practice.

[26]  Megan Lee,et al.  Effectiveness of physical activity on patients with depression and Parkinson's disease: A systematic review , 2017, PloS one.

[27]  Lena H Ting,et al.  Increased neuromuscular consistency in gait and balance after partnered, dance-based rehabilitation in Parkinson's disease. , 2017, Journal of neurophysiology.

[28]  C. Rapôso,et al.  Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model , 2015, Brain Research.

[29]  J. Doyon,et al.  Enhancing both motor and cognitive functioning in Parkinson’s disease: Aerobic exercise as a rehabilitative intervention , 2015, Brain and Cognition.

[30]  G. Knott,et al.  PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein , 2015, Acta neuropathologica communications.

[31]  N. Ibrahim,et al.  Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. , 2015, Pharmacological research.

[32]  J. Goudreau,et al.  GSK-3β dysregulation contributes to parkinson’s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein , 2014, Cell Death and Differentiation.

[33]  M. Xilouri,et al.  The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro , 2014, Neurobiology of Disease.

[34]  T. Gawlowski,et al.  Mitochondrial 8-oxoguanine glycosylase decreases mitochondrial fragmentation and improves mitochondrial function in H9C2 cells under oxidative stress conditions. , 2014, American journal of physiology. Cell physiology.

[35]  C. Dobson,et al.  Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation , 2013, PloS one.

[36]  S. McEwen,et al.  Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease , 2013, The Lancet Neurology.

[37]  E. Masliah,et al.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.

[38]  G. Deuschl,et al.  Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.

[39]  D. Hardie,et al.  Metabolism of inflammation limited by AMPK and pseudo-starvation , 2013, Nature.

[40]  Mu-ming Poo,et al.  Neurotrophin regulation of neural circuit development and function , 2012, Nature Reviews Neuroscience.

[41]  E. Masliah,et al.  The many faces of α-synuclein: from structure and toxicity to therapeutic target , 2012, Nature Reviews Neuroscience.

[42]  N. Belluardo,et al.  Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease , 2012, Cellular and Molecular Life Sciences.

[43]  T. Joh,et al.  Role of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death* , 2011, The Journal of Biological Chemistry.

[44]  A. Sidhu,et al.  Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia , 2010, Experimental Neurology.

[45]  Howard E. Gendelman,et al.  Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[46]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[47]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[48]  Bernardino Ghetti,et al.  Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders , 2006, The Journal of Neuroscience.

[49]  Kwang-Soo Kim,et al.  Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell‐specific manner , 2003, Journal of neurochemistry.

[50]  G. Siegel,et al.  Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain , 2001, Journal of Chemical Neuroanatomy.

[51]  Leslie G. Ungerleider,et al.  The acquisition of skilled motor performance: fast and slow experience-driven changes in primary motor cortex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.